AGP Executive Report
Last update: 2 hours agoM&A in Swiss pharma: Samsung Biologics is set to buy Swiss peptide CDMO PolyPeptide in a CHF 1.46bn all-cash tender offer at CHF 44.31 per share, a ~6.1% premium, with expected close by year-end and plans to squeeze out minorities and delist from SIX. Geopolitics & trade risk: The US-Iran conflict has escalated again, widening targets and raising fears the June Switzerland MoU is effectively collapsing—bad news for regional shipping and energy routes. Markets & FX watch: Pakistan’s rupee traded around 278.9–279.3 per USD, with euro near 319–322 and Swiss franc around 343.6–348.3, underscoring how currency moves can ripple into inflation and investment. Swiss-linked governance debate: The Council of Europe is questioning FIFA World Cup integrity, citing money and power pressures and a gambling sponsor deal—raising questions that could spill into future tournament rules. Business & tech: Boston Dynamics’ Spot is getting an AI “brain” using embodied AI ideas, while Swiss venture/biotech coverage highlights renewed funding momentum in the sector.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
